Chiesi Hellas

Chiesi Hellas company information, Employees & Contact Information

Explore related pages

Related company profiles:

Headquartered in Parma since 1935, Chiesi is an international company with more than 85 years of experience and a strong focus on research, development, production and the commercialization of innovative medicines in the Respiratory, Neonatology, Rare Diseases and Special Care Therapeutic Areas. Our production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). The R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team from the acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. We export to more than 70 countries with a direct presence in 26. Our aim is to be recognized as a research-focused international Group, able to develop and commercialize innovative pharmaceutical solutions to improve the quality of human life. As a B Corp in the biopharmaceutical industry, Chiesi is counted among businesses that are leading a global movement for an inclusive, equitable, and regenerative economy. We are committed to improving patient quality of life, protecting the planet and its inhabitants, supporting our communities, promoting the development of our people and guaranteeing maximum transparency in the way we work. Chiesi Hellas was established in 1998 and has a strong presence in the Greek pharmaceutical market with high rates of growth. Chiesi Hellas invests in its people and operates under the principles of fairness, equality and inclusion. We are committed to achieving results, while operating with integrity, in a socially and environmentally responsible manner. PHARMACOVIGILANCE: For any report regarding the safety of our products, as well as for Medical information, you can contact the Pharmacovigilance Department: Tel. (+30) 210 6179763 e-mail: pharmacovigilance.gr@chiesi.com

Company Details

Employees
68
Founded
-
Address
1, Renou Poggi Str., Alimos,attika 17455,greece
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
chiesi.gr
HQ
Alimos, Attika
Looking for a particular Chiesi Hellas employee's phone or email?

Chiesi Hellas Questions

News

Chiesi buys into Arbor gene editing drug for rare kidney disease - BioPharma Dive

Chiesi buys into Arbor gene editing drug for rare kidney disease BioPharma Dive

Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal - Fierce Biotech

Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal Fierce Biotech

Chiesi, Arbor Target Rare Liver Diseases in Up-to-$2.1B Gene Editing Collaboration - Genetic Engineering and Biotechnology News

Chiesi, Arbor Target Rare Liver Diseases in Up-to-$2.1B Gene Editing Collaboration Genetic Engineering and Biotechnology News

Italy’s Chiesi Raises Annual Guidance on Drug Sales Growth - Bloomberg

Italy’s Chiesi Raises Annual Guidance on Drug Sales Growth Bloomberg

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders - PR Newswire

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders PR Newswire

Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition - BioSpace

Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition BioSpace

Top Chiesi Hellas Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant